COPD exacerbation phenotypes in a real-world five year hospitalisation cohort

AsthmaCOPD

Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey

Int J Chron Obstruct Pulmon Dis

Ding B, Small M

doi: 10.2147/COPD.S136314.

RECOMMENDED

COPD

Comparative effects of LAMA-LABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Chest.

Suissa S, Dell'Aniello S, Ernst P

doi: 10.1016/j.chest.2019.11.007.

RECOMMENDED

COPDPneumonia

Real world effects of COPD medications: a cohort study with validation against RCT results

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir J.

Wing K, Williamson E, Carpenter JR, Wise L, Schneeweiss S, Smeeth L, Quint JK, Douglas I

doi: 10.1183/13993003.01586-2020. Visit the original publication at ncbi.nlm.nih.gov

COPD exacerbator phenotype: time for reassessment?

Lancet Respir Med.

Nachef Z, Mador MJ

doi: 10.1016/

RECOMMENDED

COPD

Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?

★ 2 Recommended by Dr Martin Frey, Faculty Member

Eur Respir J.

Sadatsafavi M, McCormack J, Petkau J, Lynd LD, Lee TY, Sin DD

doi: 10.1183/13993003.02122-2020.

RECOMMENDED

COPD

Real-time breath analysis reveals specific metabolic signatures of COPD exacerbations

Gaugg MT, Nussbaumer-Ochsner Y, Bregy L, Engler A, Stebler N, Gaisl T, Bruderer T, Nowak N, Sinues PM, Zenobi R, Kohler M

doi: 10.1016/j.chest.

RECOMMENDED

COPD

Efficacy of a long-term pulmonary rehabilitation maintenance program for COPD patients in a real-life setting: a 5-year cohort study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Blervaque L, Préfaut C, Forthin H, Maffre F, Bourrelier M, Héraud N, Catteau M, Pomiès P, Jaffuel D, Molinari N, Hayot M, Gouzi F

doi: 10.1186/s12931-021-01674-3

RECOMMENDED

COPD

Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Suissa S, Dell'Aniello S, Ernst P

doi: 10.1016/j.rmed.2021.106645

COPD

Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.

Int J Chron Obstruct Pulmon Dis.

Beeh KM, Beier J, Candler H, Wittig T

doi: 10.2147/COPD.S11765

Related content

Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey

Comparative effects of LAMA-LABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD

Real world effects of COPD medications: a cohort study with validation against RCT results

COPD exacerbator phenotype: time for reassessment?

Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?

Real-time breath analysis reveals specific metabolic signatures of COPD exacerbations

Efficacy of a long-term pulmonary rehabilitation maintenance program for COPD patients in a real-life setting: a 5-year cohort study

Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety

Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.